Advanced

TOP2A and HER2 gene amplification as predictors of response to anthracycline treatment in breast cancer

Villman, Kenneth ; Sjostrom, Johanna ; Heikkila, Reino ; Hultborn, Ragnar ; Malmström, Per LU ; Bengtsson, Nils-Olof ; Soderberg, Martin ; Saksela, Eero and Blomqvist, Carl (2006) In Acta Oncologica 45(5). p.590-596
Abstract
The purpose of this study was to evaluate amplification of topoisomerase IIalpha (TOP2A) and HER2 genes as predictors of response to chemotherapy in advanced breast cancer. Gene copy number of TOP2A and HER2 were analysed with chromogenic in situ hybridization (CISH) on paraffin-embedded tissue sections from the primary tumour of 85 patients treated with anthracycline containing chemotherapy. TOP2A gene amplification was present in 14 (16%) and HER2 gene amplification in 38 (45%) of the primary tumours. Two of the 14 cases with TOP2A amplification were amplified without concurrent HER2 amplification. Neither TOP2A nor HER2 gene amplification were significantly associated with response to chemotherapy (p = 0.35 and p = 0.49, respectively).
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Acta Oncologica
volume
45
issue
5
pages
590 - 596
publisher
Taylor & Francis
external identifiers
  • wos:000239275900012
  • scopus:33746746400
ISSN
1651-226X
DOI
10.1080/02841860500543182
language
English
LU publication?
yes
id
104d7805-56a8-4d55-a118-0ace7de6c81f (old id 399683)
date added to LUP
2016-04-01 16:17:42
date last changed
2020-10-04 06:14:30
@article{104d7805-56a8-4d55-a118-0ace7de6c81f,
  abstract     = {The purpose of this study was to evaluate amplification of topoisomerase IIalpha (TOP2A) and HER2 genes as predictors of response to chemotherapy in advanced breast cancer. Gene copy number of TOP2A and HER2 were analysed with chromogenic in situ hybridization (CISH) on paraffin-embedded tissue sections from the primary tumour of 85 patients treated with anthracycline containing chemotherapy. TOP2A gene amplification was present in 14 (16%) and HER2 gene amplification in 38 (45%) of the primary tumours. Two of the 14 cases with TOP2A amplification were amplified without concurrent HER2 amplification. Neither TOP2A nor HER2 gene amplification were significantly associated with response to chemotherapy (p = 0.35 and p = 0.49, respectively).},
  author       = {Villman, Kenneth and Sjostrom, Johanna and Heikkila, Reino and Hultborn, Ragnar and Malmström, Per and Bengtsson, Nils-Olof and Soderberg, Martin and Saksela, Eero and Blomqvist, Carl},
  issn         = {1651-226X},
  language     = {eng},
  number       = {5},
  pages        = {590--596},
  publisher    = {Taylor & Francis},
  series       = {Acta Oncologica},
  title        = {TOP2A and HER2 gene amplification as predictors of response to anthracycline treatment in breast cancer},
  url          = {http://dx.doi.org/10.1080/02841860500543182},
  doi          = {10.1080/02841860500543182},
  volume       = {45},
  year         = {2006},
}